164 related articles for article (PubMed ID: 35775474)
1. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells.
Lee Y; Itahana Y; Ong CC; Itahana K
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35775474
[TBL] [Abstract][Full Text] [Related]
2. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P; Zhang Y; Shi J; Li W; Gan B
J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
[TBL] [Abstract][Full Text] [Related]
3. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
4. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose.
Joly JH; Delfarah A; Phung PS; Parrish S; Graham NA
J Biol Chem; 2020 Jan; 295(5):1350-1365. PubMed ID: 31914417
[TBL] [Abstract][Full Text] [Related]
5. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11).
Yamaguchi I; Yoshimura SH; Katoh H
J Biol Chem; 2020 May; 295(20):6936-6945. PubMed ID: 32265299
[TBL] [Abstract][Full Text] [Related]
6. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P; Zhuang L; Gan B
Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
[TBL] [Abstract][Full Text] [Related]
7. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
Lien EC; Ghisolfi L; Geck RC; Asara JM; Toker A
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259101
[TBL] [Abstract][Full Text] [Related]
9. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.
Koppula P; Zhang Y; Zhuang L; Gan B
Cancer Commun (Lond); 2018 Apr; 38(1):12. PubMed ID: 29764521
[TBL] [Abstract][Full Text] [Related]
10. xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.
Liu J; Xia X; Huang P
Mol Ther; 2020 Nov; 28(11):2358-2366. PubMed ID: 32931751
[TBL] [Abstract][Full Text] [Related]
11. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucose-limited conditions.
Teramoto K; Katoh H
Cell Signal; 2019 Oct; 62():109329. PubMed ID: 31152846
[TBL] [Abstract][Full Text] [Related]
12. Cystine/glutamate antiporter xCT controls skeletal muscle glutathione redox, bioenergetics and differentiation.
Kanaan MN; Pileggi CA; Karam CY; Kennedy LS; Fong-McMaster C; Cuperlovic-Culf M; Harper ME
Redox Biol; 2024 Jul; 73():103213. PubMed ID: 38815331
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation.
Sato H; Nomura S; Maebara K; Sato K; Tamba M; Bannai S
Biochem Biophys Res Commun; 2004 Dec; 325(1):109-16. PubMed ID: 15522208
[TBL] [Abstract][Full Text] [Related]
14. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
15. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation.
Goji T; Takahara K; Negishi M; Katoh H
J Biol Chem; 2017 Dec; 292(48):19721-19732. PubMed ID: 29038291
[TBL] [Abstract][Full Text] [Related]
16. Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues.
Martis RM; Knight LJ; Donaldson PJ; Lim JC
Oxid Med Cell Longev; 2020; 2020():4594606. PubMed ID: 32655769
[TBL] [Abstract][Full Text] [Related]
17. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer.
Liu X; Olszewski K; Zhang Y; Lim EW; Shi J; Zhang X; Zhang J; Lee H; Koppula P; Lei G; Zhuang L; You MJ; Fang B; Li W; Metallo CM; Poyurovsky MV; Gan B
Nat Cell Biol; 2020 Apr; 22(4):476-486. PubMed ID: 32231310
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of cystine/glutamate antiporter in multiple sclerosis.
Pampliega O; Domercq M; Soria FN; Villoslada P; Rodríguez-Antigüedad A; Matute C
J Neuroinflammation; 2011 Jun; 8():63. PubMed ID: 21639880
[TBL] [Abstract][Full Text] [Related]
19. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor promotes glioblastoma cell death under glucose deprivation via upregulation of xCT (SLC7A11).
Yamamoto M; Teramoto K; Katoh H
Cell Signal; 2021 Feb; 78():109874. PubMed ID: 33285240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
